The zoonotic echinococcosis afflicts humans in two forms: cystic echinococcosis (CE; aka hydatidosis) and alveolar echinococcosis (AE), which are caused by tapeworms Echinococcus granulosus and E. multilocularis, respectively [[1]Wen H. Vuitton L. Tuxun T. Li J. Vuitton D.A. Zhang W. et al.Echinococcosis: advances in the 21st century.Clin Microbiol Rev. 2019; 32 (-18): e00075Crossref PubMed Scopus (384) Google Scholar]. Dogs, foxes and other carnivores are the definitive hosts, in which the mature tapeworms in their intestines produce eggs that are released into the environment. Eggs ingested by intermediate hosts (e.g., sheep, cattle, pig and camel) hatch in the intestine to release oncospheres that migrate through the portal and lymphatic vessels to the liver (main infection site) or other organs (e.g., lungs, brain, spleen and bones), where they develop into metacestodes (hydatid cysts). Humans are accidental intermediate hosts. When cysts are ingested by a definitive host, protoscoleces produced by metacestodes evaginate their scoleces that attach to the intestinal walls and develop into egg-producing adult worms [[1]Wen H. Vuitton L. Tuxun T. Li J. Vuitton D.A. Zhang W. et al.Echinococcosis: advances in the 21st century.Clin Microbiol Rev. 2019; 32 (-18): e00075Crossref PubMed Scopus (384) Google Scholar]. Among the two forms of echinococcosis, CE is much more prevalent and remains highly endemic in western China, Central Asia, South America, Mediterranean and eastern Africa. AE is only endemic in northern hemisphere, mainly in some regions of China, the Russian Federation and some countries in Europe and North America. The hardest-hit regions are the western China and Central Asia that are highly endemic for both CE and AE and accounts for 90% or more of the estimated global AE cases [[1]Wen H. Vuitton L. Tuxun T. Li J. Vuitton D.A. Zhang W. et al.Echinococcosis: advances in the 21st century.Clin Microbiol Rev. 2019; 32 (-18): e00075Crossref PubMed Scopus (384) Google Scholar, [2]Wang Q. Yang L. Wang Y. Zhang G.J. Zhong B. Wu W.P. et al.Disease burden of echinococcosis in Tibetan communities-A significant public health issue in an underdeveloped region of western China.Acta Trop. 2020; 203105283Crossref Scopus (21) Google Scholar]. Clinically, echinococcosis causes damage or dysfunction of targeted organs, mainly the liver (70% for CE and virtually 100% for AE), lung (20% for CE) and other organs (brain, spleen, kidney and heart; ∼10% for CE). Because early stages of Echinococcus infections are typically asymptomatic, most patients seeking medical care are in the late stages of CE or AE. Treatments are usually difficult with limited options [[1]Wen H. Vuitton L. Tuxun T. Li J. Vuitton D.A. Zhang W. et al.Echinococcosis: advances in the 21st century.Clin Microbiol Rev. 2019; 32 (-18): e00075Crossref PubMed Scopus (384) Google Scholar], which include long-term chemotherapy, or chemotherapy combined with puncture-aspiration-injection-reaspiration (PAIR) or surgery for CE, depending on the lesion size and stage of CE; or various surgery procedures combined with multi-year chemotherapy for AE. Currently, albendazole (ABZ) is the standard anti-echinococcosis medicine, while an analog mebendazole (MBZ) may be used as an alternative for patients experiencing severe adverse effects with ABZ [[1]Wen H. Vuitton L. Tuxun T. Li J. Vuitton D.A. Zhang W. et al.Echinococcosis: advances in the 21st century.Clin Microbiol Rev. 2019; 32 (-18): e00075Crossref PubMed Scopus (384) Google Scholar, [3]Hemphill A. Stadelmann B. Rufener R. Spiliotis M. Boubaker G. Muller J. et al.Treatment of echinococcosis: albendazole and mebendazole–what else?.Parasite. 2014; 21: 70Crossref PubMed Google Scholar, [4]Larrieu E. Gavidia C.M. Lightowlers M.W. Control of cystic echinococcosis: background and prospects.Zoonoses Public Health. 2019; 66: 889-899Crossref PubMed Scopus (51) Google Scholar]. However, ABZ has limit efficacy against echinococcosis. For example, an earlier retrospective study revealed that the recovery rates with ABZ treatment only ranged from 11.8% to 35.2% in CE cases, and 40% cases did not respond favorably [[5]Horton R.J. Albendazole in treatment of human cystic echinococcosis: 12 years of experience.Acta Trop. 1997; 64: 79-93Crossref PubMed Scopus (239) Google Scholar]. Moreover, some patients may be intolerant to ABZ/MBZ, and drug resistance to benzimidazoles are also common in helminths. Therefore, there is a keen desire to develop new and improved anti-echinococcosis drugs. In an article in EBioMedicine [[6]Li J. Wang W. Yao J. Wang T. Li S. Qi W. et al.Old drug repurposing for neglected disease: pyronaridine as a promising candidate for the treatment of Echinococcus granulosus infections.EBioMedicine. 2020; (In press)https://doi.org/https://doi.org/10.1016/j.ebiom.2020.102711Summary Full Text Full Text PDF Scopus (6) Google Scholar], Li and colleagues report a novel anti-E. granulosus activity of pyronaridine both in vitro and in vivo. Pyronaridine showed low micromolar protoscolicidal activity in vitro (EC50 = 49.0 μM), which was slightly better than ABZ (EC50 = 79.2 μM). In mouse infection model, pyronaridine impressively killed 100% of the cysts by intraperitoneal injection at 57 mg/kg/d for 3 days. When administrated orally at 57 mg/kg/d for 30 days, pyronaridine produced 90.7% cyst mortality, which is much more efficacious than ABZ (22.2% cyst mortality at 50 mg/kg/d). Based on body surface area normalization to convert drug dosage from animal studies to humans [[7]Reagan-Shaw S. Nihal M. Ahmad N. Dose translation from animal to human studies revisited.FASEB J. 2008; 22: 659-661Crossref PubMed Scopus (4312) Google Scholar], a dose of 57 mg/kg in mice is equivalent to a dose of 4.5 – 5.0 mg/kg/d in human adults (or 270 – 300 mg per 60 kg adult), which is 3 times lower than the average dose of ABZ at 15 mg/kg/d (or 900 mg per 60 kg adult) for treating human echinococcosis. For comparison, the oral dose of pyronaridine used to treat malaria in China is 24 mg/kg/d [[8]Croft S.L. Duparc S. Arbe-Barnes S.J. Craft J.C. Shin C.S. Fleckenstein L. et al.Review of pyronaridine anti-malarial properties and product characteristics.Malar J. 2012; 11: 270Crossref PubMed Scopus (89) Google Scholar]. Pyronaridine is an antimalarial drug approved for use in China since 1980s and a component of the artemisinin combination therapy pyronaridine/artesunate (Pyramax) approved by European Medicines Agency (EMA) in 2016 [[8]Croft S.L. Duparc S. Arbe-Barnes S.J. Craft J.C. Shin C.S. Fleckenstein L. et al.Review of pyronaridine anti-malarial properties and product characteristics.Malar J. 2012; 11: 270Crossref PubMed Scopus (89) Google Scholar]. Therefore, pyronaridine's preclinical and some clinical properties (e.g., pharmacokinetics and toxicity profile) are well characterized and in a good position for quickly entering clinical trials. In China and other countries where pyronaridine is an approved medicine, patients with echinococcosis might potentially benefit earlier from “off-label” prescription of pyronaridine, particularly for those with severe adverse effects or resistance to the treatment with ABZ/MBZ. In addition to advancing the study to clinical trials, it is also worth to evaluate the deworming activity of pyronaridine in dogs and other definitive hosts, which is critical in breaking the transmission cycle for both CE and AE. In addition to antimalarial and anti-echinococcosis activity, pyronaridine has be found to also possess activities against Ebola virus [[9]Lane T.R. Massey C. Comer J.E. Anantpadma M. Freundlich J.S. Davey R.A. et al.Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection.PLoS Negl Trop Dis. 2019; 13e0007890Crossref Scopus (23) Google Scholar]. However, the mechanism and mode of action of pyronaridine is not fully understood. DNA topoisomerases have been implied as the drug target in antimalarial and anti-echinococcosis activity [[6]Li J. Wang W. Yao J. Wang T. Li S. Qi W. et al.Old drug repurposing for neglected disease: pyronaridine as a promising candidate for the treatment of Echinococcus granulosus infections.EBioMedicine. 2020; (In press)https://doi.org/https://doi.org/10.1016/j.ebiom.2020.102711Summary Full Text Full Text PDF Scopus (6) Google Scholar, [8]Croft S.L. Duparc S. Arbe-Barnes S.J. Craft J.C. Shin C.S. Fleckenstein L. et al.Review of pyronaridine anti-malarial properties and product characteristics.Malar J. 2012; 11: 270Crossref PubMed Scopus (89) Google Scholar], but the evidence is not fully compelling. The recent advancement in biotechnology such as pharmacogenomics, proteomics and metabolomics may provide an opportunity to reveal the mechanism of action of pyronaridine against malaria and echinococcosis. The authors declare no conflict of interests. GZ and ML discussed the major points to be presented in this commentary; GZ drafted the manuscript; GZ and ML finalized the manuscript. Old drug repurposing for neglected disease: Pyronaridine as a promising candidate for the treatment of Echinococcus granulosus infectionsGiven its approved clinical safety, the repurposing of pyronaridine offers a rapidly translational option for treating CE including PAIR. Full-Text PDF Open Access